A treatment effect evaluation system and method based on blood physiological age calculation

Abstract

The application discloses a treatment effect evaluation system and method based on blood physiological age measurement, and belongs to the field of tools for evaluating blood treatment effects, and comprises a blood biochemical data acquisition unit, a data acquisition unit and a hospital information system are connected, and are used for acquiring user examination and inspection data, user basic information and detection schemes from the hospital information system; a treatment effect evaluation unit, the treatment effect evaluation unit is connected with a hospital business server, and is used for calculating blood physiological age according to an internal blood physiological age estimation formula, using user treatment data acquired before and after treatment, running a biological index evaluation program code to calculate blood physiological age, and then sending the calculated blood physiological age information to a user terminal through the hospital business server. The application can present treatment results in an intuitive way, so that doctors and patients can more easily understand the treatment results.

Description

Technical Field

[0001] This invention relates to the field of tools used to evaluate the efficacy of blood therapy, and more specifically, to a system and method for evaluating the efficacy of therapy based on blood physiological age calculation. Background Technology

[0002] In the past few years, blood tests have primarily been used to measure the urea reduction rate (URR) and urea clearance index (Kt / V) to understand the effectiveness of blood purification treatment in removing waste products from the body. However, these methods can only indicate whether the patient's blood urea reduction rate and urea clearance index have returned from abnormal to normal values. They cannot effectively assess the treatment effect for patients whose values ​​are already within the normal range (especially those in a sub-healthy state).

[0003] Existing methods primarily target blood purification programs, such as ozone autologous blood transfusion, and pre- and post-treatment assessments of blood purification and blood dilution. Ozone autologous blood transfusion can improve blood flow, reduce red blood cell and platelet aggregation, mitigate free radical damage, enhance immunity, improve metabolism, lower blood sugar, uric acid, blood lipids, bilirubin, and lactic acid levels, and improve blood vessel elasticity. Blood purification is a physical lipid-lowering technique. A venous access is established in the patient's arm. As blood flows through a disposable tube, it is automatically monitored and separated by a computer to remove cholesterol, triglycerides, and harmful low-density lipoprotein cholesterol. Beneficial components such as red blood cells, white blood cells, and platelets are then returned to the body, achieving lipid reduction and viscosity reduction. Most patients experience overall relief after treatment.

[0004] However, current treatments for sub-healthy individuals lack effective evaluation methods. Currently, there is no comprehensive and effective system for evaluating the efficacy of blood therapy after anti-aging or related treatments for sub-healthy individuals. Most existing methods use single indicators such as triglycerides or cholesterol in the blood to assess sleep quality or mental well-being. This method is subjective, especially for treatments like ozone autologous blood transfusion or hemodilution, where one or two blood indicators may not change significantly in the short term, making it inaccurate. Therefore, researchers urgently need tools that can evaluate the efficacy of blood therapy based on changes in blood biochemical indicators. Summary of the Invention

[0005] The purpose of this invention is to overcome the shortcomings of the prior art and provide a treatment effect evaluation system and method based on blood physiological age calculation. It can quantify the evaluation effect after blood purification treatment, analyze the biological indicators in the blood and present them in the form of age, and serve as a clinical evaluation auxiliary tool for blood purification treatment. It uses the changes in blood biological indices before and after treatment to evaluate the effect of treatment, and can present the treatment results in an intuitive way so that doctors and patients can understand the treatment results more easily.

[0006] The objective of this invention is achieved through the following solution:

[0007] A treatment efficacy evaluation system based on blood physiological age calculation includes:

[0008] A blood biochemistry data acquisition unit, which is connected to the hospital information system, is used to obtain user examination and test data, user basic information and testing plans from the hospital information system.

[0009] The treatment effect evaluation unit is connected to the hospital business server and is used to calculate the blood physiological age based on the built-in blood physiological age estimation formula, using user treatment data obtained before and after treatment, running the biometric evaluation program code, and then sending the calculated blood physiological age information to the user terminal through the hospital business server.

[0010] The user terminal is used to receive physiological age information obtained through the treatment effect evaluation unit, and is also equipped with a clinical display interface. The clinical display interface is used to display the output biological indicator values ​​and physiological age information, and to evaluate the treatment effect using the calculated blood physiological age.

[0011] Furthermore, the treatment effect evaluation unit includes: a device for receiving the patient's blood biomarker measurement values, and a device for calculating the corresponding physiological age based on the patient's blood biomarker measurement values, wherein when the blood biochemical parameter estimation formula is divided into male and female blood parameters, the measurement values ​​of the corresponding blood biomarkers for the selected patient are selected from the database according to predefined standards, and the blood biological age is calculated based on the selected measurement values.

[0012] Furthermore, the treatment effect evaluation unit also includes an adjustment unit, which is used to adjust the evaluation formula by selecting biomarkers and formula weighting indices according to actual clinical operations, so as to correct the results.

[0013] Furthermore, the device for receiving patient blood biomarker measurements includes performing the following steps:

[0014] (a) Receive one or more blood testing parameters, selected from human whole blood, serum, plasma related blood biochemical indicators, and provide a biological sample;

[0015] (b1) If the person is female, at least the following biomarkers (i) to (x) shall be measured in the corresponding biological sample:

[0016] (i) C-reflecting protein;

[0017] (ii) Glycated hemoglobin;

[0018] (iii) Cholesterol;

[0019] (iv) Alkaline phosphatase;

[0020] (v) Urine nitrogen;

[0021] (vi) Alanine aminotransferase;

[0022] (vii) Free thyroxine;

[0023] (viii) Bilirubin;

[0024] (ix) triglycerides;

[0025] (x) Fasting blood glucose

[0026] (xi) Systolic blood pressure

[0027] (b2) If the person is male, at least the following biomarkers (i) to (x) shall be determined in each biological sample, wherein the necessary biological samples are provided in step (a):

[0028] (i) C-reflecting protein;

[0029] (ii) Glycated hemoglobin;

[0030] (iii) Albumin

[0031] (iv) Cytomegalovirus;

[0032] (v) Alkaline phosphatase;

[0033] (vi) Aspartate aminotransferase;

[0034] (vii) Bilirubin;

[0035] (viii) Cholesterol;

[0036] (ix) Fasting blood glucose;

[0037] (x) urinary nitrogen

[0038] (xi) Free thyroxine

[0039] (xii) Systolic blood pressure

[0040] (c) Assess the blood biological age before and after blood treatment based on the biomarkers identified in steps (b1) / (b2) to determine the therapeutic effect.

[0041] Furthermore, the assessment of blood biological age before and after blood treatment based on the biomarkers determined in steps (b1) / (b2) to determine the treatment effect specifically uses the following blood physiological age estimation formula to measure the living age of the subject:

[0042] Male: (100.00~-100.00 constant) + (1~0.01)*{C-reactive protein} + (1~0.01)*{glycated hemoglobin} - (1~0.001)*{albumin} + (1~0.01)*{cytomegalovirus} + (1~0.001)*{alkaline phosphatase} - (1~0.0001)*{maximum expiratory volume} + (1~0.001)*{systolic blood pressure} - (1~0.01)*{bilirubin} + (1~0.01)*{free thyroxine} + (1~0.01)*{fasting blood glucose} + (0~0.5)*{aspartate aminotransferase} + (0~0.5)*{urinary nitrogen} +{actual age}

[0043] For women: (100.00 to -100.00 constant) + (1 to 0.01) * {C-reactive protein} + (1 to 0.01) * {glycated hemoglobin} + (1 to 0.01) * {cholesterol} + (1 to 0.001) * {alkaline phosphatase} - (1 to 0.0001) * {maximum expiratory volume} + (1 to 0.01) * {urine nitrogen} + (1 to 0.001) * {systolic blood pressure} + (1 to 0.01) * {bilirubin} + (1 to 0.01) * {free thyroxine} + (1 to 0.01) * {fasting blood glucose} + (0 to 0.5) * {alanine transaminase} + (0 to 0.5) * {urine nitrogen} + (0 to 5) * {triglycerides} + {actual age};

[0044] In this formula, "+" indicates the addition of values, "*" indicates the multiplication of values, the range of values ​​indicates the weighting of the importance of different blood biochemical indicators, and {} indicates the calculation of the values ​​of each blood biochemical indicator. At the beginning of the formula, a fixed value in the range of 100.00 to -100.00 will be entered. This fixed value will not change based on the test data, i.e., a constant.

[0045] In this invention, a blood physiological age analysis model based on blood biochemical indicators is provided. The above formula is obtained by analyzing the correlation coefficient between blood biochemical indicators and age in the database, as well as the biochemical parameters that are more sensitive to blood treatment by comparing patients before and after blood treatment.

[0046] Furthermore, the treatment effect evaluation unit includes a biomarker conversion module, which is used to convert the acquired blood biomarker values ​​through a predetermined method and substitute the converted biomarker values ​​into the blood physiological age estimation formula.

[0047] Furthermore, it also includes a storage unit for storing the biomarker values ​​converted by the biomarker conversion module.

[0048] Furthermore, it also includes a report generation unit for generating evaluation reports.

[0049] Furthermore, the evaluation objects of the treatment effect evaluation unit include the treatment effect on different organs and the gene prediction effect.

[0050] A method for evaluating treatment efficacy based on blood physiological age calculation, which is based on any of the above-described treatment efficacy evaluation systems based on blood physiological age calculation, and performs the following steps:

[0051] First, patient files are established on the business server. The hospital business system collects the patient's medical test data and pre-sets it in the business service system through the treatment effect evaluation unit.

[0052] Then, the relevant numerical parameters are obtained by loading and connecting the blood physiological age estimation formula model with the hospital's business system. Based on the initial parameters and patient test data, the blood anti-aging treatment effect evaluation system records the calculation results and sends the evaluation report.

[0053] The beneficial effects of this invention include:

[0054] (1) This invention can analyze the levels of one or more blood biochemical markers. Patient test data can be automatically imported from the hospital system into a blood therapy efficacy evaluation unit for calculation. Multiple relevant biomarkers are automatically selected from a pool of biomarkers. Based on specific calculation methods, changes before and after treatment can be automatically generated and presented as physiological age changes. Furthermore, this invention can generate a comprehensive score for individual patients and compare the patient's comprehensive score with one or more numerical values, corresponding to various blood biochemical parameters to identify potential disease sources, thus confirming the therapeutic effect of blood therapy on sub-health conditions.

[0055] (2) The present invention corrects the results through actual clinical operation, and the assessment formula can be flexibly adjusted by selecting biomarkers and formula weighting index.

[0056] (3) Based on the present invention, data-driven and graphical assessments can be provided, which helps to improve the accuracy and efficiency of treatment effect assessment, realize future blood health management plans, and protect life and property safety. Attached Figure Description

[0057] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0058] Figure 1 This is a structural diagram of the system according to an embodiment of the present invention;

[0059] Figure 2 This is a flowchart illustrating the workflow of the system according to an embodiment of the present invention;

[0060] Figure 3 This is the evaluation result display interface of the system in this embodiment of the invention. Detailed Implementation

[0061] The invention will be further described below with reference to the accompanying drawings and embodiments. All features disclosed in all embodiments of this specification, or steps in all methods or processes implied in the disclosure, may be combined and / or extended or substituted in any way, except for mutually exclusive features and / or steps.

[0062] Blood-based anti-aging treatments have a systemic effect, allowing for a comprehensive assessment of various blood biochemical indicators to demonstrate post-treatment differences. These treatments can activate cell metabolism, improve blood circulation, alleviate cerebral ischemia and hypoxia, and increase the oxygen content of brain cells. They alter platelet aggregation patterns in the blood, generating peroxides at sites of thrombus formation to modify thrombus development and promote thrombus dissolution. They also oxidize and remove plaques and other fatty substances adhering to blood vessel walls, increasing vascular elasticity, regulating vascular permeability, promoting wound healing, and reducing the incidence of infection.

[0063] In light of the problems mentioned in the background, the inventors of this invention further analyzed and considered the following: For patients with existing illnesses requiring blood therapy, the current clinical approach involves evaluating the main blood biochemical indicators and 3-5 secondary blood biochemical indicators. The main indicators are evaluated only after they have decreased to near-normal levels, and the secondary indicators have also improved to near-normal values. However, for those undergoing anti-aging treatment in sub-healthy individuals, the values ​​are not significantly different from those of healthy individuals. Evaluating only 5-6 indicators does not clearly reveal the differences before and after treatment. Therefore, in this invention, nearly 20 physiological parameters are selected for numerical and objective evaluation. Combined with a business service system and a hospital business system, the calculation results are visualized and presented in a user interface. The business service system can receive numerical values ​​(one or more blood biochemical indicators) from the hospital business system and then input them into the calculation formula. Through creative thinking, the inventors of this invention provide an evaluation system for identifying the therapeutic effect of blood therapy on sub-healthy individuals. Blood physiological age is developed as a general measure of an individual's physiological state, used to define whether aging is accelerated or delayed relative to actual age. In its specific implementation, this invention selects 10-25 examination or clinical chemical parameters from blood biochemical indicators. Based on the correlation between each indicator and the age of a population aged 30 to 95, blood parameters from 30 individuals aged 30 to 90 are used for calibration, and the proportions of different parameters are adjusted to better reflect the accuracy of the calculation. These parameters are clinical aging parameters, obtained during clinical examinations, including blood pressure (systolic blood pressure), metabolic markers (total cholesterol, fasting blood glucose), inflammation and infection markers (cytomegalovirus, C-reactive protein, albumin), and organ function markers (serum creatinine, alkaline phosphatase, blood urea nitrogen, maximal expiratory volume). The device provided for receiving the patient's blood biomarker measurements performs the following steps:

[0064] (a) A device for receiving patient blood biomarker measurements receives one or more blood testing parameters selected from human whole blood, serum, plasma-related blood biochemical indicators;

[0065] (b1) If the person is female, at least the following biomarkers (i) to (x) shall be determined in the relevant biological sample, wherein the necessary biological sample was provided in step (a):

[0066] (i) C-reflecting protein;

[0067] (ii) Glycated hemoglobin;

[0068] (iii) Cholesterol;

[0069] (iv) Alkaline phosphatase;

[0070] (v) Urine nitrogen;

[0071] (vi) Alanine aminotransferase;

[0072] (vii) Free thyroxine;

[0073] (viii) Bilirubin;

[0074] (ix) triglycerides;

[0075] (x) Fasting blood glucose;

[0076] (xi) Systolic blood pressure;

[0077] (b2) If the person is male, at least the following biomarkers (i) to (x) shall be determined in each biological sample, wherein the necessary biological samples are provided in step (a):

[0078] (i) C-reflecting protein;

[0079] (ii) Glycated hemoglobin;

[0080] (iii) Albumin;

[0081] (iv) Cytomegalovirus;

[0082] (v) Alkaline phosphatase;

[0083] (vi) Aspartate aminotransferase;

[0084] (vii) Bilirubin;

[0085] (viii) Cholesterol;

[0086] (ix) Fasting blood glucose;

[0087] (x) urinary nitrogen;

[0088] (xi) Free thyroxine;

[0089] (xii) systolic blood pressure;

[0090] (c) The biomarkers identified in steps (b1) / (b2) are used to assess the blood biological age before and after blood treatment to determine the therapeutic effect.

[0091] Based on the above analysis and findings of this invention, the above parameters are combined and input into the blood treatment effect evaluation unit; the evaluation formula for male and female blood physiological age health is as follows:

[0092] Male: (100.00~-100.00 constant) + (1~0.01)*{C-reactive protein} + (1~0.01)*{glycated hemoglobin} - (1~0.001)*{albumin} + (1~0.01)*{cytomegalovirus} + (1~0.001)*{alkaline phosphatase} - (1~0.0001)*{maximum expiratory volume} + (1~0.001)*{systolic blood pressure} - (1~0.01)*{bilirubin} + (1~0.01)*{free thyroxine} + (1~0.01)*{fasting blood glucose} + (0~0.5)*{aspartate aminotransferase} + (0~0.5)*{urinary nitrogen} +{actual age}

[0093] For women: (100.00 to -100.00 constant) + (1 to 0.01) * {C-reactive protein} + (1 to 0.01) * {glycated hemoglobin} + (1 to 0.01) * {cholesterol} + (1 to 0.001) * {alkaline phosphatase} - (1 to 0.0001) * {maximum expiratory volume} + (1 to 0.01) * {urine nitrogen} + (1 to 0.001) * {systolic blood pressure} + (1 to 0.01) * {bilirubin} + (1 to 0.01) * {free thyroxine} + (1 to 0.01) * {fasting blood glucose} + (0 to 0.5) * {alanine transaminase} + (0 to 0.5) * {urine nitrogen} + (0 to 5) * {triglycerides} + {actual age};

[0094] At the beginning of the formula, a fixed value in the range of 100.00 to -100.00 will be entered. This fixed value will not change based on the detected data; it is a constant.

[0095] Age was calculated using blood data from 30 volunteers, identifying 12 blood parameters that are biomarkers of aging, primarily derived from vital organs sensitive to aging. Among all biomarkers, systolic blood pressure is considered a major marker of the cardiovascular system and is closely associated with cardiovascular disease. Systolic blood pressure appears to steadily increase with age. Maximum expiratory volume (VEV) represents respiratory function and is also associated with a significant excess risk of cardiovascular disease. Therefore, VEV may be a good biomarker of aging. Blood urea nitrogen (BUN) is a traditional marker of kidney function, while C-reactive protein (CRP) is a relatively newer and more sensitive marker. Compared to BUN, CRP shows a higher correlation with chronological age. All these parameters were analyzed and converted to calculate differences before and after treatment.

[0096] like Figures 1-3 As shown, the treatment effect evaluation tool provided by this invention is an evaluation system that uses blood biological age calculation to confirm the treatment effect of ozone autologous blood transfusion, blood purification, and blood dilution in sub-healthy individuals, including:

[0097] A data source acquisition unit is connected to the hospital information system and is used to acquire user examination and test data, user basic information and testing plans from the hospital information system.

[0098] The treatment effect evaluation unit is connected to the hospital business server and is used to run the biometric evaluation program code according to the built-in algorithm, using the user treatment data obtained before and after treatment, to evaluate and calculate the biological age, and then send the biological age information to the user terminal through the hospital business server.

[0099] The user terminal is used to receive biological age information obtained through the treatment effect evaluation unit, and is equipped with a clinical display interface, which is used to display the output biological indicator values ​​and biological age information.

[0100] The treatment effect evaluation unit includes a device for receiving patient blood biomarker measurements and a device for calculating the corresponding biological age based on the patient's blood biomarker measurements. When the calculation formula is divided into male and female blood parameters, the device selects the blood biomarker measurements corresponding to the specific patient from the database according to the defined criteria and calculates the blood biological age based on the selected measurements.

[0101] This invention is used to evaluate the efficacy of blood therapy, and is particularly suitable for sub-healthy individuals, especially middle-aged people (e.g., 30 to 90 years old). By identifying differences in certain blood biochemical parameters before and after treatment, and through data-driven evaluation, comparing the relative effects before and after treatment, it assesses the potential of the blood therapy intervention as an anti-aging or anti-aging treatment. The system of this invention has the following advantages:

[0102] 1) Scalability: The system should be able to handle the ever-increasing amount of data.

[0103] 2) Flexibility: The system design can be quickly changed to respond to new requirements and the formulas can be modified based on experience, while maintaining data integrity.

[0104] 3) Security: The system ensures that all patient data, formulas, and software are protected from external threats, disasters, and damage.

[0105] 4) Manageability: No local software installation is required; minimal management is needed; new versions and updates are easy to implement and access, and no local training is required.

[0106] In other embodiments, the present invention can provide a technical solution for predicting the likelihood of an individual developing age-related diseases, including the following:

[0107] (a) Quantify the expression level of each individual in blood biochemical indicators;

[0108] (b) Compare the expression levels of the different calculation formulas for men and women provided in step (a) with the actual age levels; thus, by using the formulas to express the changes in the blood biochemical index levels of sub-healthy patients after blood treatment, it can indicate the risk of an individual developing age-related diseases or the presence of age-related diseases.

[0109] The present invention has the following advantages:

[0110] (1) This invention uses twelve tests, and using so few tests would limit the accuracy of the calculated combinatorial biological age. In addition, the twelve tests are the same for every patient.

[0111] (2) The twelve tests are basically routine hospital tests, and none of them involve any additional tests, which means that measurements can be obtained quickly from the customer.

[0112] (3) Each client undergoes twelve tests to generate a combined biological age measurement, which is a separate process. Client data is not stored or transferred from one treatment course to the next, so each assessment is about how things have changed from one treatment course to the next.

[0113] (4) The blood biochemical parameters are introduced into the blood aging formula to convert them into information on the quantitative comprehensive blood physiological age value, so as to comprehensively evaluate the changes in blood physiological age after blood treatment and understand its treatment effect.

[0114] (5) This invention provides a computational system for evaluating the treatment effect of an individual after blood anti-aging treatment or assisting in the diagnosis of blood aging-related diseases or predicting the likelihood of organ failure in an individual. This method is applicable to clients aged 30-80 years. The invention includes the following steps: (i) quantifying the expression level of blood parameters in a blood biochemical sample from an individual; (ii) comparing the blood physiological age expression level quantified in step (i) with the actual age; changes in expression levels indicate changes in the effectiveness of blood treatment; and wherein a method is used to select from one or more blood biochemical indicators; (b) different weighted calculation methods for men and women; (c) performing computer analysis on each parameter obtained in steps (a) and (b) and displaying the combined results in a graphical manner.

[0115] (6) Changes in the expression levels of blood biochemical markers as defined in this invention indicate an individual's risk of developing age-related diseases. If aging characteristics are opposed or suppressed after blood treatment, i.e., the expression of an analyte that is upregulated with age increases or the expression of an analyte that is downregulated with age decreases compared to the control value, this is indicative of a reduced risk of developing age-related diseases, or of having age-related diseases, or of a reduced mortality rate.

[0116] (7) The present invention can accurately assess an individual’s post-blood treatment assessment, thus identifying a high risk of developing age-related blood diseases, and can take corresponding blood treatment actions to reduce the risk.

[0117] (8) This invention can quantify the effect of blood purification treatment and analyze the biological indicators in the blood to present them in the form of age. As a clinical assessment tool for blood purification treatment, it can use the changes in blood biological indices before and after treatment to judge the effect of treatment. It can present the treatment results in an intuitive way so that doctors and patients can understand the treatment results more easily.

[0118] The units described in the embodiments of the present invention can be implemented in software or hardware, and the described units can also be located in a processor. The names of these units do not necessarily limit the specific unit itself.

[0119] According to one aspect of the present invention, a computer program product or computer program is provided, the computer program product or computer program including computer instructions stored in a computer-readable storage medium. A processor of a computer device reads the computer instructions from the computer-readable storage medium, and executes the computer instructions, causing the computer device to perform the methods provided in the various alternative implementations described above.

[0120] In another aspect, the present invention also provides a computer-readable medium, which may be included in the electronic device described in the above embodiments; or it may exist independently and not assembled into the electronic device. The computer-readable medium carries one or more programs that, when executed by the electronic device, cause the electronic device to perform the methods described in the above embodiments.

[0121] All parts not covered in this invention are the same as or can be implemented using existing technologies.

[0122] The above technical solution is only one embodiment of the present invention. For those skilled in the art, based on the application methods and principles disclosed in the present invention, it is easy to make various types of improvements or modifications, and not limited to the methods described in the above specific embodiments of the present invention. Therefore, the methods described above are only preferred and are not restrictive.

[0123] In addition to the examples above, other embodiments may be obtained by those skilled in the art based on the above disclosure or by making modifications using knowledge or technology in related fields. The features of each embodiment may be interchanged or replaced. Modifications and changes made by those skilled in the art that do not depart from the spirit and scope of the present invention should be within the protection scope of the appended claims.

Claims

1. A treatment efficacy evaluation system based on blood physiological age calculation, characterized in that, This is used to assess the effectiveness of ozone autologous blood transfusion, blood purification, and blood dilution therapy in sub-healthy individuals by calculating their physiological blood age. Specifically, it includes: A blood biochemistry data acquisition unit, which is connected to the hospital information system, is used to obtain user examination and test data, user basic information and testing plans from the hospital information system. The treatment effect evaluation unit is connected to the hospital business server and is used to calculate the blood physiological age based on the built-in blood physiological age estimation formula, using user treatment data obtained before and after treatment, running the biometric evaluation program code, and then sending the calculated blood physiological age information to the user terminal through the hospital business server. The user terminal is used to receive blood physiological age information obtained through the treatment effect evaluation unit, and is also equipped with a clinical display interface. The clinical display interface is used to display the output biological indicator values ​​and blood physiological age information, and to evaluate the treatment effect using the calculated blood physiological age. The treatment effect evaluation unit includes: a device for receiving the patient's blood biomarker measurement values, and a device for calculating the corresponding blood physiological age based on the patient's blood biomarker measurement values. When the blood biochemical parameter estimation formula is divided into male and female blood parameters, the measurement values ​​of the corresponding blood biomarkers for the selected patient are selected from the database according to a predefined standard, and the blood physiological age is calculated based on the selected measurement values. The device for receiving patient blood biomarker measurements includes performing the following steps: (a) Receive one or more blood testing parameters, selected from human whole blood, serum, plasma-related blood biochemical indicators, and provide a biological sample; (b1) If the person is female, at least the following biomarkers (i) to (x) shall be measured in the corresponding biological sample: (i) C-reactive protein; (ii) Glycated hemoglobin; (iii) Cholesterol; (iv) Alkaline phosphatase; (v) Urine nitrogen; (vi) Alanine aminotransferase; (vii) Free thyroxine; (viii) Bilirubin; (ix) triglycerides; (x) Fasting blood glucose; (xi) Systolic blood pressure; (b2) If the person is male, at least the following biomarkers (i) to (x) shall be determined in each biological sample, wherein the necessary biological samples are provided in step (a): (i) C-reactive protein; (ii) Glycated hemoglobin; (iii) Albumin; (iv) Cytomegalovirus; (v) Alkaline phosphatase; (vi) Aspartate aminotransferase; (vii) Bilirubin; (ix) Fasting blood glucose; (x) Urine nitrogen; (xi) Free thyroxine; (xii) Systolic blood pressure; (c) Assess the blood biological age before and after blood treatment based on the biomarkers identified in steps (b1) / (b2) to determine the therapeutic effect.

2. The treatment effect evaluation system based on blood physiological age calculation according to claim 1, characterized in that, The treatment efficacy evaluation unit also includes an adjustment unit, which is used to adjust the evaluation formula by selecting biomarkers and formula weighting indices according to actual clinical operations, so as to correct the results.

3. The treatment effect evaluation system based on blood physiological age calculation according to claim 1, characterized in that, The treatment effect evaluation unit includes a biomarker conversion module, which is used to convert the values ​​of the acquired blood biomarkers using a predetermined method, and then substitute the converted biomarker values ​​into the blood physiological age estimation formula.

4. The treatment effect evaluation system based on blood physiological age calculation according to claim 3, characterized in that, It also includes a storage unit for storing the biomarker values ​​converted by the biomarker conversion module.

5. The treatment effect evaluation system based on blood physiological age calculation according to claim 1, characterized in that, It also includes a report generation unit for generating evaluation reports.

Images